Blog

Patrick Forde: Interesting ODAC for future perioperative trial designs

Photo of Patrick Forde from facebook.com

Jul 27, 2024, 02:50

Patrick Forde: Interesting ODAC for future perioperative trial designs

Patrick Forde, Professor at the Johns Hopkins University, shared a post on X by FDA Oncology, adding:

“Interesting ODAC (Oncologic Drugs Advisory Committee), future perioperative trial designs should consider contribution of phases but AEGEAN (neoadjuvant chemo-durva followed by adjuvant durva) looks like it will be approved. Would have been difficult not to do so post approval of KN671 with a very similar design.”

Quoting FDA Oncology’s post:

“Oncologic Drugs Advisory Committee votes 11 to 0 in favor of FDA requiring that new trial design proposals for perioperative regimens for resectable NSCLC include adequate within trial assessment of contribution of treatment phase.”

Screen capture of a voting result with date and time displayed as "7/25/2024, 1:31:57 PM." The table shows names under "Yes" including Ashley Rosko, MD, Azam Ghafoor, MD, and others, totaling 11 votes. The "No" and "Abstain" categories record 0 votes.

Link to video.
Sources: Patrick Forde/X and FDA Oncology/X

AEGEAN Aegean Trial cancer Durvalumab FDA Oncology Johns Hopkins University KN671 non small cell lung cancer NSCLC ODAC OncoDaily Oncologic Drugs Advisory Committee Oncology Patrick Forde

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Former Disney CEO Bob Chapek Appointed Senior Adviser at SCAN Group

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage